884 related articles for article (PubMed ID: 8938795)
21. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin.
Chang JY; Liu JF; Juang SH; Liu TW; Chen LT
Cancer Res; 2002 Jul; 62(13):3716-21. PubMed ID: 12097280
[TBL] [Abstract][Full Text] [Related]
22. Expression of cell-cycle mediators in ovarian cancer cells after transfection with p16(INK4a), p21(WAF1/Cip-1), and p53.
Ramirez PT; Gershenson DM; Tortolero-Luna G; Ramondetta LM; Fightmaster D; Wharton JT; Wolf JK
Gynecol Oncol; 2001 Dec; 83(3):543-8. PubMed ID: 11733969
[TBL] [Abstract][Full Text] [Related]
23. Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin.
Kolfschoten GM; Hulscher TM; Schrier SM; van Houten VM; Pinedo HM; Boven E
Gynecol Oncol; 2002 Mar; 84(3):404-12. PubMed ID: 11855878
[TBL] [Abstract][Full Text] [Related]
24. Antisense protein kinase A RIalpha acts synergistically with hydroxycamptothecin to inhibit growth and induce apoptosis in human cancer cells: molecular basis for combinatorial therapy.
Cho YS; Cho-Chung YS
Clin Cancer Res; 2003 Mar; 9(3):1171-8. PubMed ID: 12631623
[TBL] [Abstract][Full Text] [Related]
25. Resistance to apoptosis induced by alkylating agents in v-Ha-ras-transformed cells due to defect in p53 function.
Kuo ML; Chou YW; Chau YP; Huang TS
Mol Carcinog; 1997 Apr; 18(4):221-31. PubMed ID: 9142217
[TBL] [Abstract][Full Text] [Related]
26. Acute and delayed apoptosis induced by thymidine deprivation correlates with expression of p53 and p53-regulated genes in colon carcinoma cells.
Harwood FG; Frazier MW; Krajewski S; Reed JC; Houghton JA
Oncogene; 1996 May; 12(10):2057-67. PubMed ID: 8668331
[TBL] [Abstract][Full Text] [Related]
27. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen.
Goldwasser F; Bae I; Valenti M; Torres K; Pommier Y
Cancer Res; 1995 May; 55(10):2116-21. PubMed ID: 7743511
[TBL] [Abstract][Full Text] [Related]
28. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin.
Kapoor R; Slade DL; Fujimori A; Pommier Y; Harker WG
Oncol Res; 1995; 7(2):83-95. PubMed ID: 7579731
[TBL] [Abstract][Full Text] [Related]
29. Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance.
Wang LF; Ting CY; Lo CK; Su JS; Mickley LA; Fojo AT; Whang-Peng J; Hwang J
Cancer Res; 1997 Apr; 57(8):1516-22. PubMed ID: 9108454
[TBL] [Abstract][Full Text] [Related]
30. Induction of apoptosis in breast cancer cells by TPA.
Li Y; Bhuiyan M; Mohammad RM; Sarkar FH
Oncogene; 1998 Dec; 17(22):2915-20. PubMed ID: 9879997
[TBL] [Abstract][Full Text] [Related]
31. Acquired camptothecin resistance of human breast cancer MCF-7/C4 cells with normal topoisomerase I and elevated DNA repair.
Fujimori A; Gupta M; Hoki Y; Pommier Y
Mol Pharmacol; 1996 Dec; 50(6):1472-8. PubMed ID: 8967967
[TBL] [Abstract][Full Text] [Related]
32. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro.
Bowman KJ; Newell DR; Calvert AH; Curtin NJ
Br J Cancer; 2001 Jan; 84(1):106-12. PubMed ID: 11139322
[TBL] [Abstract][Full Text] [Related]
33. Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis.
Walton MI; Whysong D; O'Connor PM; Hockenbery D; Korsmeyer SJ; Kohn KW
Cancer Res; 1993 Apr; 53(8):1853-61. PubMed ID: 8467505
[TBL] [Abstract][Full Text] [Related]
34. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
[TBL] [Abstract][Full Text] [Related]
35. Implication of p53 in growth arrest and apoptosis induced by the synthetic retinoid CD437 in human lung cancer cells.
Sun SY; Yue P; Wu GS; El-Deiry WS; Shroot B; Hong WK; Lotan R
Cancer Res; 1999 Jun; 59(12):2829-33. PubMed ID: 10383141
[TBL] [Abstract][Full Text] [Related]
36. Effects of topoisomerase II inhibitors on gastric cancer cells characterized by different genetic lesions.
Scovassi AL; Pellegata NS; Di Stefano L; Padovan L; Negri C; Prosperi E; Riva F; Ciomei M; Ranzani GN
Anticancer Res; 2001; 21(4A):2803-8. PubMed ID: 11724358
[TBL] [Abstract][Full Text] [Related]
37. The role of the Ataxia telangiectasia gene in the p53, WAF1/CIP1(p21)- and GADD45-mediated response to DNA damage produced by ionising radiation.
Artuso M; Esteve A; Brésil H; Vuillaume M; Hall J
Oncogene; 1995 Oct; 11(8):1427-35. PubMed ID: 7478567
[TBL] [Abstract][Full Text] [Related]
38. Differential induction of etoposide-mediated apoptosis in human leukemia HL-60 and K562 cells.
Ritke MK; Rusnak JM; Lazo JS; Allan WP; Dive C; Heer S; Yalowich JC
Mol Pharmacol; 1994 Oct; 46(4):605-11. PubMed ID: 7969039
[TBL] [Abstract][Full Text] [Related]
39. Discrepancy between the initial DNA damage and cell survival after camptothecin treatment in two murine lymphoma L5178Y sublines.
Gradzka I; Szumiel I
Cell Biochem Funct; 1996 Sep; 14(3):163-71. PubMed ID: 8888569
[TBL] [Abstract][Full Text] [Related]
40. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.
Eng WK; McCabe FL; Tan KB; Mattern MR; Hofmann GA; Woessner RD; Hertzberg RP; Johnson RK
Mol Pharmacol; 1990 Oct; 38(4):471-80. PubMed ID: 2172765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
